Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and LABA/inhaled corticosteroid (ICS) FDCs are threatened by uptake of these therapies. However, many patients persist on long-acting therapies for long periods of time before switching, making it difficult for new therapies to gain a foothold. Due to the progressive and irreversible nature of COPD, many patients eventually end up being prescribed a combination including a LABA, LAMA, and ICS, but often struggle to pay for necessary treatment, which can lead to relatively low rates of compliance.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently-treated and newly diagnosed COPD patients?
- How have LABA/LAMAFDCs been integrated into the treatment algorithm?
- What proportion of COPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of COPD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug treated patients with COPD?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.